Genmab initiates phase III trial with drug against cervical cancer

Positive phase II results prompt Genmab and its collaborative partner Seattle Genetics to submit a US registration application for accelerated approval, which is given to drugs that accommodate an unmet need for the treatment of serious illnesses.

Photo: Joost Melis / Genmab / PR

The biotech firm Genmab will be initiating a phase III trial program with Tisotumab Vedotin for the treatment of cervical cancer with the aim of assessing its efficiency compared with chemotherapy for patients with recurrent or metastatic cervical cancer, according to a Genmab statement on Monday evening.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs